Abstract
In order to discover compounds that may be useful in the prevention of Alzheimer disease, a drug library was screened for drugs that could decrease amyloid β peptide (Aβ) accumulation secreted from a human CNS-derived cell line. Of the 2160 compounds subjected to a primary screen, 16, or 0.74%, reduced Ab accumulation by at least 40%. Seven of these compounds were confirmed to be effective in a secondary screen using each compound at a dose of 5 μM. Three of these seven compounds were more effective than the others at reducing Aβ levels in a tertiary screen, and led to 68 to 85% reductions in total Aβ, at the 25 μM dosage. The effects of these three drugs on secreted Aβ40, Aβ42, and sAPPα were also determined. Thus, we have identified lead compounds that may be useful for subsequent studies to determine the mechanism of action of each drug, as well as for pre-clinical studies to determine whether each of these drugs is safe and effective in vivo.
Keywords: amyloid peptide, drug screen, amyloid precursor protein
Current Alzheimer Research
Title: Drug Library Screen to Identify Compounds that Decrease Secreted Aβ from a Human Cell Line
Volume: 2 Issue: 2
Author(s): Enakshi Chakrabarti and Jonathan D. Smith
Affiliation:
Keywords: amyloid peptide, drug screen, amyloid precursor protein
Abstract: In order to discover compounds that may be useful in the prevention of Alzheimer disease, a drug library was screened for drugs that could decrease amyloid β peptide (Aβ) accumulation secreted from a human CNS-derived cell line. Of the 2160 compounds subjected to a primary screen, 16, or 0.74%, reduced Ab accumulation by at least 40%. Seven of these compounds were confirmed to be effective in a secondary screen using each compound at a dose of 5 μM. Three of these seven compounds were more effective than the others at reducing Aβ levels in a tertiary screen, and led to 68 to 85% reductions in total Aβ, at the 25 μM dosage. The effects of these three drugs on secreted Aβ40, Aβ42, and sAPPα were also determined. Thus, we have identified lead compounds that may be useful for subsequent studies to determine the mechanism of action of each drug, as well as for pre-clinical studies to determine whether each of these drugs is safe and effective in vivo.
Export Options
About this article
Cite this article as:
Chakrabarti Enakshi and Smith D. Jonathan, Drug Library Screen to Identify Compounds that Decrease Secreted Aβ from a Human Cell Line, Current Alzheimer Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567205053585738
DOI https://dx.doi.org/10.2174/1567205053585738 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
O-Arylation of Iodophenols with 2-Fluorobenzaldehyde Under Microwave Conditions
Letters in Drug Design & Discovery Utilizing Delta Opioid Receptors and Peptides for Cytoprotection: Implications in Stroke and Other Neurological Disorders
CNS & Neurological Disorders - Drug Targets A Systematic Review of Current Progresses in the Nucleic Acid-Based Therapies for Neurodegeneration with Implications for Alzheimer’s Disease
Mini-Reviews in Medicinal Chemistry Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?
Current Pharmaceutical Design Catalytic Activity of Certain Antibodies as a Potential Tool for Drug Synthesis and for Directed Prodrug Therapies
Current Medicinal Chemistry Liver X Receptor-Mediated Gene Regulation and Cholesterol Homeostasis in Brain: Relevance to Alzheimers Disease Therapeutics
Current Alzheimer Research Lithium and its Neuroprotective and Neurotrophic Effects: Potential Treatment for Post-Ischemic Stroke Sequelae
Current Drug Targets Efficient Synthesis of 5-Arylmethyl-5-phenylimidazolidine-2,4-dione (or 5-Arylmethyl-5-phenyl-2-thioxoimidazolidin-4-one) from Chalcone Oxides Under Ultrasound Irradiation
Letters in Organic Chemistry Combination of Electrochemical, Spectrometric and Other Analytical Techniques for High Throughput Screening of Pharmaceutically Active Compounds
Combinatorial Chemistry & High Throughput Screening Genetically Modified Mice Models for Alzheimers Disease
Current Topics in Medicinal Chemistry Cerebrospinal Fluid proNGF: A Putative Biomarker for Early Alzheimer’s Disease
Current Alzheimer Research A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design Editorial (Thematic Issue : Gut Permeability and the Microbiome: Emerging Roles in CNS Function in Health and Disease)
Current Pharmaceutical Design Design, Synthesis and Acetylcholinesterase and Butylcholinesterase Inhibition Activity of Novel 1-(Alkyl)-3-(2-oxo-2H-chromenyloxy Acetamido) methylpyridinium Salts
Letters in Organic Chemistry Molecular Modeling of Substances Isolated from the Essential Oil of the Species <i>Drimys angustifolia</i> and <i>Drimys brasiliensis</i>
Current Physical Chemistry Cocaine Dependence and Stroke: Pathogenesis and Management
Current Neurovascular Research Commentary [Research Highlights : Neurotrophic Factor Treatment of Neurological Disorders: The Benefits of a Pleiotropic Treatment Approach]
CNS & Neurological Disorders - Drug Targets Genetic Variation Underlying Psychosis-inducing Effects of Cannabis: Critical Review and Future Directions
Current Pharmaceutical Design Confocal Microscopy Evidence of Prion Protein Fragment hPrP[173-195] Internalization in Rat B104 Neuroblastoma Cell Line
Protein & Peptide Letters Neurobehavioral Consequences Associated with Long Term Tramadol Utilization and Pathological Mechanisms
CNS & Neurological Disorders - Drug Targets